For CEA, while it is upregulated in 90% of advanced CRC (34), it is not reliably used for prognosis, and studies have shown an unacceptably low sensitivity for recurrent CRC of 32–37% (35–37). This evidence concerns the gene CEACAM5 and colorectal carcinoma.